Ipsen weighs U.S. manufacturing investment for neuroscience drugs
Ipsen’s CEO said the company has $2.3 billion available for deals and is considering a potential U.S. manufacturing plant that would focus on neuroscience drugs; Ipsen also indicated it might look for deals to complement its migraine drug business.